When technology precedes regulation: the challenges and opportunities of e-pharmacy in low-income and middle-income countries.
health policy
health systems
public health
qualitative study
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
19
02
2021
revised:
16
04
2021
accepted:
01
05
2021
entrez:
21
5
2021
pubmed:
22
5
2021
medline:
2
6
2021
Statut:
ppublish
Résumé
The recent growth of medicine sales online represents a major disruption to pharmacy markets, with COVID-19 encouraging this trend further. While e-pharmacy businesses were initially the preserve of high-income countries, in the past decade they have been growing rapidly in low-income and middle-income countries (LMICs). Public health concerns associated with e-pharmacy include the sale of prescription-only medicines without a prescription and the sale of substandard and falsified medicines. There are also non-health-related risks such as consumer fraud and lack of data privacy. However, e-pharmacy may also have the potential to improve access to medicines. Drawing on existing literature and a set of key informant interviews in Kenya, Nigeria and India, we examine the e-pharmacy regulatory systems in LMICs. None of the study countries had yet enacted a regulatory framework specific to e-pharmacy. Key regulatory challenges included the lack of consensus on regulatory models, lack of regulatory capacity, regulating sales across borders and risks of over-regulation. However, e-pharmacy also presents opportunities to enhance medicine regulation-through consolidation in the sector, and the traceability and transparency that online records offer. The regulatory process needs to be adapted to keep pace with this dynamic landscape and exploit these possibilities. This will require exploration of a range of innovative regulatory options, collaboration with larger, more compliant businesses, and engagement with global regulatory bodies. A key first step must be ensuring that national regulators are equipped with the necessary awareness and technical expertise to actively oversee this e-pharmacy activity.
Identifiants
pubmed: 34016578
pii: bmjgh-2021-005405
doi: 10.1136/bmjgh-2021-005405
pmc: PMC8141442
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Pharm World Sci. 2009 Jun;31(3):351-61
pubmed: 19343530
Eur J Prev Cardiol. 2020 Dec;27(19):2334-2337
pubmed: 31914793
Int J Health Serv. 2007;37(2):279-89
pubmed: 17665724
Health Policy Plan. 2016 Mar 8;31(7):940-953
pubmed: 26962123
Soc Sci Med. 2018 Sep;212:9-16
pubmed: 29986284
Eur J Public Health. 2009 Aug;19(4):375-7
pubmed: 19151103
Br Med Bull. 2016 Jun;118(1):110-26
pubmed: 27151957
Am Health Drug Benefits. 2014 Jun;7(4):216-24
pubmed: 25126373
BMC Proc. 2020 Jul 23;14(Suppl 10):9
pubmed: 32714444
Inform Health Soc Care. 2011 Jan;36(1):20-34
pubmed: 21208091
J Antimicrob Chemother. 2017 May 1;72(5):1521-1528
pubmed: 28333179
Ann Health Law. 2001;10:75-103
pubmed: 11496591
J Glob Health. 2019 Jun;10(1):010301
pubmed: 32082543
Subst Abuse Treat Prev Policy. 2020 Feb 18;15(1):16
pubmed: 32070374
Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):970-6
pubmed: 20652863
BMC Health Serv Res. 2012 Jul 27;12:223
pubmed: 22838649
Soc Sci Med. 2013 Nov;97:220-7
pubmed: 24016728
Bull World Health Organ. 2020 Jul 1;98(7):449-457
pubmed: 32742030